Opportunities and challenges of the use of the hospital exemption in the early-stage development of novel cellular therapies

Advanced Therapy Medicinal Products (ATMPs), particularly novel cellular therapies, represent a significant technological advancement in medicine. These transformative therapies offer personalised and potentially curative treatments for rare, ultra rare and life-threatening diseases. However, their development and clinical use are often limited by regulatory inconsistencies and manufacturing, logistics, and access challenges. Aim: This research explores the role of the Hospital Exemption (HE) pathway within the European Union (EU) in facilitating early access to personalised novel cellular therapies for patients with unmet medical needs where, there are no alternative treatments available. Methodology: A mixed-methods approach was employed to investigate the regulatory variations across the EU, manufacturing and logistical challenges, and ethical concerns associated with the use of the HE pathway. The research also examined unique opportunities that the HE pathway could provide to drive innovation and improve patient access, particularly for therapies developed in academic settings. Results: The main findings of this research highlight the need for harmonised regulations, improved transparency, and standardised data collection across Member States for the HE pathway. Conclusion: Based on these findings, the research provides recommendations to optimise the HE pathway’s potential in supporting early-stage development of novel cellular therapies while maintaining patient safety and public trust.